エルレアダ （ERLEADA）が前立腺がん患者の死亡リスクを低減

ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Lowered Risk of Metastasis or Death in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
February 8, 2018　 Janssen, Prostate cancer

• Phase 3 SPARTAN data showed ERLEADA™ improved median metastasis-free survival by more than two years
• Data featured as oral presentation at ASCO GU 2018 (Abstract #161) and published in The New England Journal of Medicine

次世代のアンドロゲン受容体阻害薬アパルタマイド（予定販売名：エルレアダ ERLEADA）が非転移性・去勢抵抗性の前立腺がん患者において転移または死亡のリスクを低減した。